Press releases

Learn more about our company, latest clinical developments and breakthroughs in liver diseases. Subscribe to news and follow us on social media.

All news
Press releases

Dec 20, 2021

Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

Nov 15, 2021

Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis

Oct 19, 2021

Versantis Appoints Leading Hepatologist Prof Dr Katharina Staufer as Chief Medical Officer

Sep 7, 2021

Versantis Receives U.S. FDA Orphan Drug Designation for VS-01

Mar 17, 2021

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis

Feb 5, 2021

Versantis Appoints Seasoned Pharma Executive Christopher Seaton to Board

Oct 19, 2020

Versantis Receives FDA Rare Pediatric Disease Designation for VS-01 for the Treatment of Urea Cycle Disorders

Sep 18, 2019

Versantis closes CHF 16M Series B financing round to advance clinical development of novel therapeutics for liver disease

Aug 15, 2019

Successful initiation for FiH Study with VS-01

Dec 18, 2018

Versantis Strengthens Leadership Team with Appointment of Dr. Med.Sophie Biguenet as Chief Medical Officer

Mar 19, 2018

Versantis Establishes Medical Advisory Board comprising five notorious international authorities in hepatology, intensive care, and nephrology. They joined versantis to transform the care of acute liver diseases.

Jul 17, 2017

Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure

Mar 29, 2017

VERSANTIS RAISES CHF 4.4 MILLION IN SERIES A FINANCING TO ADVANCE NEW GENERATION OF LIVER DISEASE MEDICINES

May 17, 2016

The EMA issued a positive opinion on the orphan drug designation for VS-01 for the treatment of acute liver failure.

Subscribe and receive the latest news

Thank you. Your message has been sent to us.

Error! There was an error sending your message.

TERMS & CONDITIONS

COOKIES & PRIVACY POLICY